Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
October 14 2020 - 7:00AM
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical
company focused on developing and commercializing novel cancer
therapeutics to reactivate mutant tumor suppressor protein, p53,
today announced the launch of p53reactivation.com. The new website
contributes to Aprea’s disease awareness initiative to educate
healthcare professionals on the importance of p53 mutations in
cancer and reactivation of mutant p53 as a potential therapeutic
option for the treatment of cancer.
“Mutations in p53 are present in approximately half of all
cancers and are often associated with poor treatment outcomes and
resistance to traditional anti-cancer therapies,” said Eyal Attar,
M.D., Senior Vice President and Chief Medical Officer of Aprea
Therapeutics. “Knowledge of the poor prognoses that accompany p53
mutations, the availability of diagnostic tests for their
identification, and awareness of mutant p53 reactivation as a
potential targeted therapeutic option, may collectively advance
detection and treatment for cancer patients with this important and
significant unmet medical need.”
Corporate Contacts:
Scott M. CoianteSr. Vice President and Chief Financial
Officer617-463-9385
Gregory A. KorbelVice President of Business
Development617-463-9385
Source: Aprea Therapeutics, Inc.
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jul 2023 to Jul 2024